enVeno Medical Corporation successfully completes its rebranding
The company now trades under the ticker symbol “NVNO”
IRVINE, CA / ACCESSWIRE / October 1, 2021 / enVVeno Medical Corporation (NASDAQ: NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today announced that it has successfully completed its change in brand and that its shares are now traded under the ticker symbol “NVNO” on the Nasdaq Capital Market. The company was previously called Hancock Jaffe Laboratories, Inc.
For shareholders of the Company holding shares in electronic form, the name change will not require any action. Shareholders with physical share certificates should contact the Company’s transfer agent to obtain new certificates.
For more information, please visit the Company’s new website at www.enVeno.com.
About enVeno Medical Corporation
enVeno Medical (NASDAQ: NVNO) is an Irvine, Calif., Medical device company focused on developing innovative bioprosthetic (tissue-based) solutions to improve the quality of care in the treatment of venous disease. The company’s flagship product, VenoValve®, is a first-class implant developed for the treatment of chronic deep vein insufficiency (CVI). In healthy patients, the valves inside the leg veins help push blood up the leg and back to the heart and lungs. Affecting an estimated 2.4 million people in the United States, CVI occurs when the valves inside the veins in the leg are damaged, causing blood to flow back (reflux), a pool of blood in the lower part of the leg. leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and have become chronic. Implanted in the femoral vein, the VenoValve is designed to act as a one-way valve, to help restore good blood flow to the leg. The VenoValve is currently being evaluated in the pivotal SAVVE study with data expected by the end of 2022.
Caution regarding forward-looking statements
This press release and all statements made by the shareholders, directors, employees, representatives and partners of enVeno Medical Corporation (the “Company”) contain, or may contain, among others, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, but are not limited to, statements identified by words such as “plans”, “may”, “will”, “could”, “should”, “should”, “believe”, “s ‘expects to’, ‘plans’, ‘estimates’, ‘intentions’, ‘plans’, ‘potential’ or similar expressions. These statements are based on the current beliefs and expectations of the management of the Company and are subject to significant risks and uncertainties, including those detailed in the documents filed by the Company with the Securities and Exchange Commission. Actual results (including, without limitation, with respect to our name change, our progress with VenoValve, and the planned timeline related to the SAAVE US pivotal trial, including when to start patient enrollment, VenoValve’s ability to meet the unmet medical needs of CVI sufferers and our development of a second device for the treatment of venous disease) may differ materially from those stated or implied in any forward-looking statements. These forward-looking statements involve certain risks and uncertainties which are subject to change depending on various factors (many of which are beyond the control of the Company). The Company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
Jenene Thomas, JTC Team, LLC
Michelle McAdam, Chronic Communications, Inc.
THE SOURCE: enVeno Medical Corporation
See the source version on accesswire.com: